JVI Email Content Delivery
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
JVI Accepts, published online ahead of print on 7 May 2008
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Lamirande, E. W.
Right arrow Articles by Subbarao, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamirande, E. W.
Right arrow Articles by Subbarao, K.
J. Virol. doi:10.1128/JVI.00304-08
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

A live attenuated SARS coronavirus is immunogenic and efficacious in golden Syrian hamsters

Elaine W. Lamirande, Marta L. DeDiego, Anjeanette Roberts, Jadon P. Jackson, Enrique Alvarez, Tim Sheahan, Wun-Ju Shieh, Sherif R. Zaki, Ralph Baric, Luis Enjuanes, and Kanta Subbarao*

Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892; Dept. of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB), Nacional de Biotecnología (CSIC), Campus Universidad Autónoma, Darwin 3, Cantoblanco, 28049 Madrid, Spain; Dept. of Epidemiology, Univ. of North Carolina, Chapel Hill, NC 27599; Infectious Diseases Pathology Activity, Centers for Disease Control and Prevention, Atlanta, GA 30333

* To whom correspondence should be addressed. Email: ksubbarao{at}niaid.nih.gov.


  Abstract

The immunogenicity and protective efficacy of a live attenuated vaccine consisting of a recombinant SARS coronavirus lacking the E gene (rSARS-CoV-{Delta}E) was studied in hamsters. Hamsters immunized with rSARS-CoV-{Delta}E developed high serum neutralizing antibody titers and were protected from replication of homologous (SARS-CoV Urbani) and heterologous SARS-CoV (GD03) in the upper and lower respiratory tract. rSARS-CoV-{Delta}E-immunized hamsters remained active following wild-type virus challenge while mock-immunized hamsters displayed decreased activity. Despite being attenuated in replication in the respiratory tract, rSARS-CoV-{Delta}E virus is an immunogenic and efficacious vaccine in hamsters.




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.